609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019
Publication
, Conference
Freedland, SJ; Sandin, R; Tagawa, ST; Klaassen, Z; Bitting, RL; Ramaswamy, K; Emir, B; Bland, C; Hong, A; Yang, H; Gao, W; Song, W; George, DJ
Published in: Annals of Oncology
September 2021
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S650 / S651
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Freedland, S. J., Sandin, R., Tagawa, S. T., Klaassen, Z., Bitting, R. L., Ramaswamy, K., … George, D. J. (2021). 609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019. In Annals of Oncology (Vol. 32, pp. S650–S651). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.1122
Freedland, S. J., R. Sandin, S. T. Tagawa, Z. Klaassen, R. L. Bitting, K. Ramaswamy, B. Emir, et al. “609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019.” In Annals of Oncology, 32:S650–51. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.1122.
Freedland SJ, Sandin R, Tagawa ST, Klaassen Z, Bitting RL, Ramaswamy K, et al. 609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019. In: Annals of Oncology. Elsevier BV; 2021. p. S650–1.
Freedland, S. J., et al. “609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S650–51. Crossref, doi:10.1016/j.annonc.2021.08.1122.
Freedland SJ, Sandin R, Tagawa ST, Klaassen Z, Bitting RL, Ramaswamy K, Emir B, Bland C, Hong A, Yang H, Gao W, Song W, George DJ. 609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019. Annals of Oncology. Elsevier BV; 2021. p. S650–S651.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S650 / S651
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis